Search

Your search keyword '"Boyle, Jay O."' showing total 291 results
Start Over Author "Boyle, Jay O."
291 results on '"Boyle, Jay O."'

1. Post-operative PET/CT improves the detection of early recurrence of squamous cell carcinomas of the oral cavity

Author

Yu, Yao, Schöder, Heiko, Zakeri, Kaveh, Chen, Linda, Kang, Jung Julie, McBride, Sean Matthew, Tsai, C. Jillian, Gelblum, Daphna Y., Boyle, Jay O., Cracchiolo, Jennifer R., Cohen, Marc A., Singh, Bhuvanesh, Ganly, Ian, Patel, Snehal G., Michel, Loren S., Dunn, Lara, Sherman, Eric J., Pfister, David G., Wong, Richard J., Riaz, Nadeem, and Lee, Nancy Y.

Published
2023
Full Text
View/download PDF

2. Hypoxia-Directed Treatment of Human Papillomavirus–Related Oropharyngeal Carcinoma

Author

Lee, Nancy Y., primary, Sherman, Eric J., additional, Schöder, HeiKo, additional, Wray, Rick, additional, Boyle, Jay O., additional, Singh, Bhuvanesh, additional, Grkovski, Milan, additional, Paudyal, Ramesh, additional, Cunningham, Louise, additional, Zhang, Zhigang, additional, Hatzoglou, Vaios, additional, Katabi, Nora, additional, Diplas, Bill H., additional, Han, James, additional, Imber, Brandon S., additional, Pham, Khoi, additional, Yu, Yao, additional, Zakeri, Kaveh, additional, McBride, Sean M., additional, Kang, Jung J., additional, Tsai, C. Jillian, additional, Chen, Linda C., additional, Gelblum, Daphna Y., additional, Shah, Jatin P., additional, Ganly, Ian, additional, Cohen, Marc A., additional, Cracchiolo, Jennifer R., additional, Morris, Luc G.T., additional, Dunn, Lara A., additional, Michel, Loren S., additional, Fetten, James V., additional, Kripani, Anuja, additional, Pfister, David G., additional, Ho, Alan L., additional, Shukla-Dave, Amita, additional, Humm, John L., additional, Powell, Simon N., additional, Li, Bob T., additional, Reis-Filho, Jorge S., additional, Diaz, Luis A., additional, Wong, Richard J., additional, and Riaz, Nadeem, additional

Published
2024
Full Text
View/download PDF

3. A novel surgeon credentialing and quality assurance process using transoral surgery for oropharyngeal cancer in ECOG-ACRIN Cancer Research Group Trial E3311

Author

Ferris, Robert L., Flamand, Yael, Holsinger, F. Christopher, Weinstein, Gregory S., Quon, Harry, Mehra, Ranee, Garcia, Joaquin J., Hinni, Michael L., Gross, Neil D., Sturgis, Erich M., Duvvuri, Umamaheswar, Méndez, Eduardo, Ridge, John A., Magnuson, J. Scott, Higgins, Kerry A., Patel, Mihir R., Smith, Russel B., Karakla, Daniel W., Kupferman, Michael E., Malone, James P., Judson, Benjamin L., Richmon, Jeremy, Boyle, Jay O., Bayon, Rodrigo, O'Malley, Bert W., Jr, Ozer, Enver, Thomas, Giovana R., Koch, Wayne M., Bell, R. Bryan, Saba, Nabil F., Li, Shuli, Sigurdson, Elin R., and Burtness, Barbara

Published
2020
Full Text
View/download PDF

4. RAS-Mutated Cytologically Indeterminate Thyroid Nodules: Prevalence of Malignancy and Behavior Under Active Surveillance.

Author

Sfreddo, Hannah J., Koh, Elizabeth S., Zhao, Karena, Swartzwelder, Christina E., Untch, Brian R., Marti, Jennifer L., Roman, Benjamin R., Dublin, Jared, Wang, Ronald S., Xia, Rong, Cohen, Jean-Marc, Xu, Bin, Ghossein, Ronald, Givi, Babak, Boyle, Jay O., Tuttle, R. Michael, Fagin, James A., Wong, Richard J., and Morris, Luc G.T.

Subjects
WATCHFUL waiting, RAS oncogenes, THYROID nodules, THYROID cancer, TUMOR growth, SOLITARY pulmonary nodule
Abstract

Background: Genomic profiling is now available for risk stratification of cytologically indeterminate thyroid nodules (ITNs). Mutations in RAS genes (HRAS, NRAS, KRAS) are found in both benign and malignant thyroid nodules, although isolated RAS mutations are rarely associated with aggressive tumors. Because the long-term behavior of RAS-mutant ITNs is not well understood, most undergo immediate surgery. In this multicenter retrospective cohort study, we characterize tumor growth kinetics of RAS-mutant ITNs followed with active surveillance (AS) using serial ultrasound (US) scans and examine the histopathologic diagnoses of those surgically resected. Methods: US and histopathologic data were analyzed retrospectively from two cohorts: (1) RAS-mutant ITNs managed with AS at three institutions (2010–2023) and (2) RAS-mutant ITNs managed with immediate surgery at two institutions (2016–2020). AS cohort subjects had ≥3 months of follow-up and two or more US scans. Cumulative incidence of nodule growth was determined by the Kaplan–Meier method and growth by ≥72% change in tumor volume. Pathological diagnoses for the immediate surgery cohort were analyzed separately. Results: Sixty-two patients with 63 RAS-mutated ITNs under AS had a median diameter of 1.7 cm (interquartile range [IQR] 1.2–2.6) at time of diagnosis. During a median AS period of 23 months (IQR 9.5–53.5 months), growth was observed in 12 of 63 nodules (19.0%), with a cumulative incidence of 1.9% (1 year), 23.0% (3 years), and 28.0% (5 years). Most nodules (81.0%) demonstrated stability. Surgery was ultimately performed in 6 nodules, of which 1 (16.7%) was malignant. In the cohort of 209 RAS-mutant ITNs triaged to immediate surgery, 33% were malignant (23.9% American Thyroid Association [ATA] low-risk cancers, 7.2% ATA intermediate-risk, and 1.9% ATA high-risk. During a median follow-up of 6.9 (IQR 4.4–7.1) years, there were no disease-specific deaths in these patients. Conclusions: We describe the behavior of RAS-mutant ITNs under AS and find that most demonstrate stability over time. Of the resected RAS-mutant nodules, most were benign; of the cancers, most were ATA low-risk. Immediate surgical resection of all RAS-mutant ITNs appears to be a low-value practice. Further research is needed to help define cases most appropriate for AS or immediate surgery. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Last-line local treatment with the Quad Shot regimen for previously irradiated head and neck cancers

Author

Fan, Dan, Kang, Jung J., Fan, Ming, Wang, Huili, Lee, Anna, Yu, Yao, Chen, Linda, Jillian Tsai, C., McBride, Sean M., Riaz, Nadeem, Gelblum, Daphna Y., Neal, Brian P., Fetten, James, Dunn, Lara A., Michel, Loren S., Boyle, Jay O., Cohen, Marc A., Roman, Benjamin R., Ganly, Ian, Singh, Bhuvanesh, Wong, Richard J., Sherman, Eric J., and Lee, Nancy Y.

Published
2020
Full Text
View/download PDF

6. Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial

Author

William, William N, Papadimitrakopoulou, Vassiliki, Lee, J Jack, Mao, Li, Cohen, Ezra EW, Lin, Heather Y, Gillenwater, Ann M, Martin, Jack W, Lingen, Mark W, Boyle, Jay O, Shin, Dong M, Vigneswaran, Nadarajah, Shinn, Nancy, Heymach, John V, Wistuba, Ignacio I, Tang, Ximing, Kim, Edward S, Saintigny, Pierre, Blair, Elizabeth A, Meiller, Timothy, Gutkind, J Silvio, Myers, Jeffrey, El-Naggar, Adel, and Lippman, Scott M

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Genetics, Clinical Trials and Supportive Activities, Clinical Research, Prevention, Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Detection, screening and diagnosis, 4.2 Evaluation of markers and technologies, Administration, Oral, Anticarcinogenic Agents, Disease-Free Survival, Double-Blind Method, Drug Administration Schedule, ErbB Receptors, Erlotinib Hydrochloride, Female, Humans, Loss of Heterozygosity, Male, Middle Aged, Mouth Neoplasms, Precancerous Conditions, Prospective Studies, Protein Kinase Inhibitors, Risk Assessment, Risk Factors, Time Factors, Treatment Outcome, United States, Receptor, Epidermal Growth Factor, Public Health and Health Services, Oncology and carcinogenesis
Abstract

ImportanceStandard molecularly based strategies to predict and/or prevent oral cancer development in patients with oral premalignant lesions (OPLs) are lacking.ObjectiveTo test if the epidermal growth factor receptor inhibitor erlotinib would reduce oral cancer development in patients with high-risk OPLs defined by specific loss of heterozygosity (LOH) profiles. Secondary objectives included prospective determination of LOH as a prognostic marker in OPLs.DesignThe Erlotinib Prevention of Oral Cancer (EPOC) study was a randomized, placebo-controlled, double-bind trial. Accrual occurred from November 2006 through July 2012, with a median follow-up time of 35 months in an ambulatory care setting in 5 US academic referral institutions. Patients with OPLs were enrolled in the protocol, and each underwent LOH profiling (N = 379); they were classified as high-risk (LOH-positive) or low-risk (LOH-negative) patients based on their LOH profiles and oral cancer history. The randomized sample consisted of 150 LOH-positive patients.InterventionsOral erlotinib treatment (150 mg/d) or placebo for 12 months.Main outcomes and measuresOral cancer-free survival (CFS).ResultsA total of 395 participants were classified with LOH profiles, and 254 were classified LOH positive. Of these, 150 (59%) were randomized, 75 each to the placebo and erlotinib groups. The 3-year CFS rates in placebo- and erlotinib-treated patients were 74% and 70%, respectively (hazard ratio [HR], 1.27; 95% CI, 0.68-2.38; P = .45). The 3-year CFS was significantly lower for LOH-positive compared with LOH-negative groups (74% vs 87%, HR, 2.19; 95% CI, 1.25-3.83; P = .01). Increased EGFR gene copy number correlated with LOH-positive status (P

Published
2016

7. A preliminary analysis of patient reported outcomes following posterolateral mandible reconstruction: The role of flap type

Author

Cohen, Zack, primary, Zhang, Kevin K., additional, Kim, Minji, additional, Haglich, Kathryn, additional, Woods, Jack, additional, Monge, Jasmine, additional, Matros, Evan, additional, Boyle, Jay O., additional, McCarthy, Colleen, additional, Cracchiolo, Jennifer R., additional, Cohen, Marc A., additional, Shahzad, Farooq, additional, Nelson, Jonas A., additional, and Allen, Robert J., additional

Published
2023
Full Text
View/download PDF

9. Miniplate Versus Reconstruction Bar Fixation for Oncologic Mandibular Reconstruction with Free Fibula Flaps.

Author

Cohen, Zack, Graziano, Francis D., Shamsunder, Meghana G., Shahzad, Farooq, Boyle, Jay O., Cohen, Marc A., Matros, Evan, Nelson, Jonas A., and Allen Jr., Robert J.

Subjects
MANDIBLE surgery, FREE flaps, SURGICAL complications, COMPUTER-aided design
Abstract

Background Fibula free flaps (FFF) are the gold standard tissue for the reconstruction of segmental mandibular defects. A comparison of miniplate (MP) and reconstruction bar (RB)-based fixation of FFFs has been previously described in a systematic review; however, long-term, single-center studies comparing the two plating methods are lacking. The authors aim to examine the complication profile between MPs and RBs at a single tertiary cancer center. We hypothesized that increased components and a lack of rigid fixation inherent to MPs would lead to higher rates of hardware exposure/failure. Methods A retrospective review was performed from a prospectively maintained database at Memorial Sloan Kettering Cancer Center. All patients who underwent FFF-based reconstruction of mandibular defects between 2015 and 2021 were included. Data on patient demographics, medical risk factors, operative indications, and chemoradiation were collected. The primary outcomes of interest were perioperative flap-related complications, long-term union rates, osteoradionecrosis (ORN), return to the operating room (OR), and hardware exposure/failure. Recipient site complications were further stratified into two groups: early (<90 days) and late (>90 days). Results In total, 96 patients met the inclusion criteria (RB = 63, MP = 33). Patients in both groups were similar with respect to age, presence of comorbidities, smoking history, and operative characteristics. The mean follow-up period was 17.24 months. In total, 60.6 and 54.0% of patients in the MP and RB cohorts received adjuvant radiation, respectively. There were no differences in rates of hardware failure overall; however, in patients with an initial complication after 90 days, MPs had significantly higher rates of hardware exposure (3 vs. 0, p = 0.046). Conclusion MPs were found to have a higher risk of exposed hardware in patients with a late initial recipient site complication. It is possible that improved fixation with highly adaptive RBs designed by computer-aided design/manufacturing technology explains these results. Future studies are needed to assess the effects of rigid mandibular fixation on patient-reported outcome measures in this unique population. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Data from Effects of Cigarette Smoke on the Human Oral Mucosal Transcriptome

Author

Boyle, Jay O., primary, Gümüş, Zeynep H., primary, Kacker, Ashutosh, primary, Choksi, Vishal L., primary, Bocker, Jennifer M., primary, Zhou, Xi Kathy, primary, Yantiss, Rhonda K., primary, Hughes, Duncan B., primary, Du, Baoheng, primary, Judson, Benjamin L., primary, Subbaramaiah, Kotha, primary, and Dannenberg, Andrew J., primary

Published
2023
Full Text
View/download PDF

21. Evaluation of Proton Therapy Reirradiation for Patients With Recurrent Head and Neck Squamous Cell Carcinoma

Author

Lee, Anna, primary, Woods, Robbie, additional, Mahfouz, Amgad, additional, Kitpanit, Sarin, additional, Cartano, Olivia, additional, Mohamed, Nader, additional, Youssef, Irini, additional, Marqueen, Kathryn, additional, Sine, Kevin, additional, Mah, Dennis, additional, Neal, Brian, additional, Zakeri, Kaveh, additional, Kang, Jung J., additional, Riaz, Nadeem, additional, Yu, Yao, additional, McBride, Sean M., additional, Chen, Linda D., additional, Tsai, C. Jillian, additional, Gelblum, Daphna Y., additional, Press, Robert H., additional, Michel, Loren S., additional, Sherman, Eric J., additional, Pfister, David, additional, Dunn, Lara A., additional, Ho, Alan L., additional, Fetten, James, additional, Wong, Richard J., additional, Boyle, Jay O., additional, Singh, Bhuvanesh, additional, Cracchiolo, Jennifer R., additional, Ganly, Ian, additional, Cohen, Marc A., additional, and Lee, Nancy Y., additional

Published
2023
Full Text
View/download PDF

23. Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Oropharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy

Author

Youssef, Irini, primary, Yoon, Jennifer, additional, Mohamed, Nader, additional, Zakeri, Kaveh, additional, Press, Robert H., additional, Chen, Linda, additional, Gelblum, Daphna Y., additional, McBride, Sean M., additional, Tsai, Chiaojung Jillian, additional, Riaz, Nadeem, additional, Yu, Yao, additional, Cohen, Marc A., additional, Dunn, Lara Ann, additional, Ho, Alan L., additional, Wong, Richard J., additional, Michel, Loren S., additional, Boyle, Jay O., additional, Singh, Bhuvanesh, additional, Kriplani, Anuja, additional, Ganly, Ian, additional, Sherman, Eric J., additional, Pfister, David G., additional, Fetten, James, additional, and Lee, Nancy Y., additional

Published
2022
Full Text
View/download PDF

24. Consensuses, controversies, and future directions in treatment deintensification for human papillomavirus‐associated oropharyngeal cancer

Author

Kang, Jung Julie, primary, Yu, Yao, additional, Chen, Linda, additional, Zakeri, Kaveh, additional, Gelblum, Daphna Yael, additional, McBride, Sean Matthew, additional, Riaz, Nadeem, additional, Tsai, C. Jillian, additional, Kriplani, Anuja, additional, Hung, Tony K. W., additional, Fetten, James V., additional, Dunn, Lara A., additional, Ho, Alan L., additional, Boyle, Jay O., additional, Ganly, Ian S., additional, Singh, Bhuvanesh, additional, Sherman, Eric J., additional, Pfister, David G., additional, Wong, Richard J., additional, and Lee, Nancy Y., additional

Published
2022
Full Text
View/download PDF

27. Patterns of Treatment Failure and Postrecurrence Outcomes Among Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma After Chemoradiotherapy Using Modern Radiation Techniques

Author

Leeman, Jonathan E., Li, Jin-gao, Pei, Xin, Venigalla, Praveen, Zumsteg, Zachary S., Katsoulakis, Evangelia, Lupovitch, Eitan, McBride, Sean M., Tsai, Chiaojung J., Boyle, Jay O., Roman, Benjamin R., Morris, Luc G. T., Dunn, Lara A., Sherman, Eric J., Lee, Nancy Y., and Riaz, Nadeem

Published
2017
Full Text
View/download PDF

32. The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers: Insights From a Precision Oncology Sequencing Platform

Author

Morris, Luc G. T., Chandramohan, Raghu, West, Lyndsay, Zehir, Ahmet, Chakravarty, Debyani, Pfister, David G., Wong, Richard J., Lee, Nancy Y., Sherman, Eric J., Baxi, Shrujal S., Ganly, Ian, Singh, Bhuvanesh, Shah, Jatin P., Shaha, Ashok R., Boyle, Jay O., Patel, Snehal G., Roman, Benjamin R., Barker, Christopher A., McBride, Sean M., Chan, Timothy A., Dogan, Snjezana, Hyman, David M., Berger, Michael F., Solit, David B., Riaz, Nadeem, and Ho, Alan L.

Published
2017
Full Text
View/download PDF

33. Consensuses, controversies, and future directions in treatment deintensification for human papillomavirus‐associated oropharyngeal cancer.

Author

Kang, Jung Julie, Yu, Yao, Chen, Linda, Zakeri, Kaveh, Gelblum, Daphna Yael, McBride, Sean Matthew, Riaz, Nadeem, Tsai, C. Jillian, Kriplani, Anuja, Hung, Tony K. W., Fetten, James V., Dunn, Lara A., Ho, Alan L., Boyle, Jay O., Ganly, Ian S., Singh, Bhuvanesh, Sherman, Eric J., Pfister, David G., Wong, Richard J., and Lee, Nancy Y.

Subjects
OROPHARYNGEAL cancer, HUMAN papillomavirus, SURGICAL robots, INDIVIDUALIZED medicine, PATIENT selection, WARTS
Abstract

The most common cancer caused by human papillomavirus (HPV) infection in the United States is oropharyngeal cancer (OPC), and its incidence has been rising since the turn of the century. Because of substantial long‐term morbidities with chemoradiation and the favorable prognosis of HPV‐positive OPC, identifying the optimal deintensification strategy for this group has been a keystone of academic head‐and‐neck surgery, radiation oncology, and medical oncology for over the past decade. However, the first generation of randomized chemotherapy deintensification trials failed to change the standard of care, triggering concern over the feasibility of de‐escalation. National database studies estimate that up to one third of patients receive nonstandard de‐escalated treatments, which have subspecialty‐specific nuances. A synthesis of the multidisciplinary deintensification data and current treatment standards is important for the oncology community to reinforce best practices and ensure optimal patient outcomes. In this review, the authors present a summary and comparison of prospective HPV‐positive OPC de‐escalation trials. Chemotherapy attenuation compromises outcomes without reducing toxicity. Limited data comparing transoral robotic surgery (TORS) with radiation raise concern over toxicity and outcomes with TORS. There are promising data to support de‐escalating adjuvant therapy after TORS, but consensus on treatment indications is needed. Encouraging radiation deintensification strategies have been reported (upfront dose reduction and induction chemotherapy‐based patient selection), but level I evidence is years away. Ultimately, stage and HPV status may be insufficient to guide de‐escalation. The future of deintensification may lie in incorporating intratreatment response assessments to harness the powers of personalized medicine and integrate real‐time surveillance. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

35. Flexible fiber‐based CO 2 laser vs monopolar cautery for resection of oral cavity lesions: A single center randomized controlled trial assessing pain and quality of life following surgery

Author

Rosenthal, Matthew, primary, Baser, Raymond E., additional, Migliacci, Jocelyn, additional, Boyle, Jay O., additional, Morris, Luc G. T., additional, Cohen, Marc A., additional, Singh, Bhuvanesh, additional, Shah, Jatin P., additional, Wong, Richard J., additional, Patel, Snehal, additional, and Ganly, Ian, additional

Published
2021
Full Text
View/download PDF

38. Any day, split halfway: Flexibility in scheduling high‐dose cisplatin—A large retrospective review from a high‐volume cancer center

Author

Kang, Jung Julie, primary, Tchekmedyian, Vatche, additional, Mohammed, Nader, additional, Rybkin, Alisa, additional, Kitpanit, Sarin, additional, Fan, Ming, additional, Wang, Huili, additional, Lobaugh, Stephanie M., additional, Zhang, Zhigang, additional, Lee, Anna, additional, Chen, Linda, additional, Yu, Yao, additional, Zakeri, Kaveh, additional, Gelblum, Daphna Y., additional, Riaz, Nadeem, additional, McBride, Sean M., additional, Tsai, C. Jillian, additional, Cohen, Marc A., additional, Cracchiolo, Jennifer R., additional, Morris, Luc G., additional, Singh, Bhuvanesh, additional, Patel, Snehal, additional, Ganly, Ian, additional, Boyle, Jay O., additional, Wong, Richard J., additional, Eng, Juliana, additional, Zhi, Wanqing Iris, additional, Ng, Kenneth, additional, Ho, Alan L., additional, Dunn, Lara A., additional, Michel, Loren, additional, Fetten, James V., additional, Pfister, David G., additional, Lee, Nancy Y., additional, and Sherman, Eric J., additional

Published
2021
Full Text
View/download PDF

40. Contributors

Author

Adamson, Peter A., primary, Adler, Joshua S., additional, Ali, M. Jafer, additional, Anderson, Susan K., additional, Ashbach, Matthew, additional, Auerbach, Andrew D., additional, Barrs, David, additional, Bhatki, Amol M., additional, Bilsky, Mark H., additional, Boyle, Jay O., additional, Bruley, Mark E., additional, Bumpous, Jeffrey M., additional, Chang, C. Y. Joseph, additional, Chen, Amy Y., additional, Chen, Theodore, additional, Chepeha, Douglas B., additional, Cheung, Steven W., additional, Ciucci, Michelle, additional, Civantos, Francisco J., additional, Cockerham, Kimberly P., additional, Coltrera, Marc D., additional, Courey, Mark S., additional, Craig, Brian, additional, Deschler, Daniel G., additional, Dierdorf, Stephen F., additional, Dowd, Christopher F., additional, Eisele, David W., additional, El-Sayed, Ivan H., additional, Feghali, Joseph G., additional, Ferris, Robert L., additional, Fraioli, Rebecca E., additional, Fried, Marvin P., additional, Gassner, Holger G., additional, Gausas, Roberta E., additional, Genden, Eric M., additional, Gibson, F. Brian, additional, Gillespie, M. Boyd, additional, Goldberg, Andrew N., additional, Goldstein, David P., additional, Gourin, Christine G., additional, Gullane, Patrick J., additional, Haigentz, Missak, additional, Hoffman, Ronald A., additional, Horn, Corinne Elisabeth, additional, Hu, Mimi I., additional, Hullar, Timothy E., additional, Inglis, Andrew F., additional, Irish, Jonathan C., additional, Jackman, Alexis H., additional, Jacobson, Adam S., additional, Johnson, Jonas T., additional, Kashima, Haskins, additional, Kezirian, Eric J., additional, Khabie, Nissim, additional, Kim, David W., additional, Koch, Wayne M., additional, Kölln, Karen A., additional, Kraus, Dennis H., additional, Lambert, Paul R., additional, Lin, Frank R., additional, Lin, Jerry, additional, Little, Jarrod, additional, Lobo, Errol P., additional, Lustig, Lawrence R., additional, McCulloch, Timothy M., additional, McDermott, Michael W., additional, McElveen, John T., additional, Millender, Laura Ellen, additional, Moe, Kris S., additional, Monsein, Lee H., additional, Moore, Eric J., additional, Murakami, Craig S., additional, Murr, Andrew H., additional, Netterville, James L., additional, Niparko, John K., additional, Olsen, Kerry D., additional, Orloff, Lisa A., additional, Ow, Thomas Julian, additional, Parikh, Sanjay R., additional, Parikh, Shatul L., additional, Pellegrini, Francesca, additional, Perkins, Stephen W., additional, Perler, Bruce A., additional, Pitman, Karen T., additional, Pogrel, M. Anthony, additional, Pusceddu, Elisabetta, additional, Rainone, Francine, additional, Reid, Vincent, additional, Resto, Vicente A., additional, Rhodes, Jennifer L., additional, Richardson, Mark A., additional, Saito, David M., additional, Saleh, Hazem Mohammad Ali, additional, Schiff, Bradley A., additional, Schmidt, Brian L., additional, Senior, Brent A., additional, Sherman, Steven I., additional, Shrime, Mark G., additional, Smith, Richard V., additional, Staffenberg, David Alan, additional, Straker, Tracey, additional, Sykes, Jonathan M., additional, Teknos, Theodoros N., additional, Terris, David J., additional, Thedinger, Bradley, additional, Thomas, J. Regan, additional, Wachter, Robert M., additional, Walvekar, Rohan R., additional, Wang, Brian S., additional, Wang, Steven J., additional, Wladis, Edward, additional, Zavod, Matthew B., additional, Zimbler, Mark S., additional, Zoumalan, Christopher I., additional, and Zoumalan, Richard A., additional

Published
2009
Full Text
View/download PDF

42. The 3 Bs of cancer care amid the COVID‐19 pandemic crisis: “Be safe, be smart, be kind”—A multidisciplinary approach increasing the use of radiation and embracing telemedicine for head and neck cancer

Author

Kang, Jung Julie, primary, Wong, Richard J., additional, Sherman, Eric J., additional, Rybkin, Alisa, additional, McBride, Sean M., additional, Riaz, Nadeem, additional, Tsai, C. Jillian, additional, Yu, Yao, additional, Chen, Linda, additional, Zakeri, Kaveh, additional, Gelblum, Daphna Y., additional, Gillespie, Erin F., additional, Cohen, Marc A., additional, Cracchiolo, Jennifer R., additional, Ganly, Ian, additional, Patel, Snehal, additional, Singh, Bhuvanesh, additional, Boyle, Jay O., additional, Roman, Benjamin R., additional, Morris, Luc G., additional, Shaha, Ashok R., additional, Dunn, Lara A., additional, Ho, Alan L., additional, Fetten, James V., additional, Shah, Jatin P., additional, Pfister, David G., additional, and Lee, Nancy Y., additional

Published
2020
Full Text
View/download PDF

43. CLO20-041: Prognostic Factors in Major Salivary Gland Tumors Treated with Adjuvant Radiation Therapy

Author

Kang, Jung Julie, primary, Verma, Hannah, additional, Zakeri, Kaveh, additional, Wang, Huili, additional, Fan, Dan, additional, Fan, Ming, additional, Lee, Anna, additional, Kitpanit, Sarin, additional, Chen, Linda, additional, Yu, Yao, additional, Tsai, C. Jillian, additional, McBride, Sean, additional, Riaz, Nadeem, additional, Gelblum, Daphna, additional, Ho, Alan S., additional, Sherman, Eric, additional, Dunn, Lara, additional, Boyle, Jay O., additional, Wong, Richard J., additional, Ganly, Ian, additional, and Lee, Nancy Y., additional

Published
2020
Full Text
View/download PDF

44. Temporal Lobe Necrosis in Head and Neck Cancer Patients after Proton Therapy to the Skull Base

Author

Kitpanit, Sarin, primary, Lee, Anna, primary, Pitter, Ken L., primary, Fan, Dan, primary, Chow, James C.H., primary, Neal, Brian, primary, Han, Zhiqiang, primary, Fox, Pamela, primary, Sine, Kevin, primary, Mah, Dennis, primary, Dunn, Lara A., primary, Sherman, Eric J., primary, Michel, Loren, primary, Ganly, Ian, primary, Wong, Richard J., primary, Boyle, Jay O., primary, Cohen, Marc A., primary, Singh, Bhuvanesh, primary, Brennan, Cameron W., primary, Gavrilovic, Igor T., primary, Hatzoglou, Vaios, primary, O'Malley, Bernard, primary, Zakeri, Kaveh, primary, Yu, Yao, primary, Chen, Linda, primary, Gelblum, Daphna Y., primary, Kang, Jung Julie, primary, McBride, Sean M., primary, Tsai, Chiaojung J., primary, Riaz, Nadeem, primary, and Lee, Nancy Y., primary

Published
2020
Full Text
View/download PDF

45. Outcomes and toxicities of definitive radiotherapy and reirradiation using 3‐dimensional conformal or intensity‐modulated (pencil beam) proton therapy for patients with nasal cavity and paranasal sinus malignancies

Author

Fan, Ming, primary, Kang, Jung Julie, additional, Lee, Anna, additional, Fan, Dan, additional, Wang, Huili, additional, Kitpanit, Sarin, additional, Fox, Pamela, additional, Sine, Kevin, additional, Mah, Dennis, additional, McBride, Sean M., additional, Tsai, Chiaojung Jillian, additional, Riaz, Nadeem, additional, Dunn, Lara A., additional, Sherman, Eric J., additional, Michel, Loren, additional, Singh, Bhuvanesh, additional, Ganly, Ian, additional, Wong, Richard J., additional, Boyle, Jay O., additional, Cohen, Marc A., additional, and Lee, Nancy Y., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results